VEGFA and cancer: While increasing clinical evidence has suggested the immunological effects of Bevacizumab on T cells in cancer patients, much less is known about the potential impact of anti-VEGF treatment on vascular ECs, which are potent immune regulator cells that function by forming the blood–tissue barrier in control of the trafficking of various leukocyte populations [28,29,30].